Sonnet BioTherapeutics (SONN) 10-Q2024 Q1 Quarterly report

Filed: 13 Feb 25, 4:15pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. sophomore Avg

New words: AEs, age, aiming, Albany, Alkem, alkylating, appointed, appointment, autonomic, baseline, Biology, buyer, Cellular, Center, certified, CH, chemotherapeutic, clarify, COBRA, cohort, coincident, competitive, complement, Comprehensive, Consortium, consummate, copy, coverage, CPA, currency, de, Department, derivative, Donald, double, Dr, earliest, embedded, equivalent, escalation, EU, European, family, feedback, firm, forward, founder, FTE, Griffith, health, herewith, highest, host, IIOC, Immuno, ineligible, institutional, intermittent, inventory, irinotecan, Japan, joining, leiomyosarcoma, liposarcoma, liposomal, McAndrew, member, metastatic, mild, Molecular, molecule, move, NALIRIFOX, NK, Ohio, Oswego, OTLK, Outlook, owed, oxaliplatin, package, pancreatic, passage, phenotype, PIPE, predecessor, prolonged, proportionately, prorated, prospectively, purport, put, reach, RECIST, refractory, regimen, release, released, resignation, retention, Russia, salary, Sarcoma, Schedule, Science, secrete, selected, Senior, settlement, size, Squibb, standby, Stephen, Stolz, STS, submission, Subtopic, syndrome, text, TME, trabectedin, transient, unbilled, underlying, underway, University, unresectable, utilize, Vice, withholding, York, Zealand

Removed: advantaged, antiviral, assist, authorization, bankruptcy, breach, BTIG, buy, cancelled, commencing, corporate, DIPN, DNA, enacted, excise, executing, expired, Extensible, greatest, Hong, Inflation, insolvency, instrumental, intent, IRA, Kong, Language, large, negotiate, offered, pandemic, Princeton, ProteoNic, ranging, remaining, Republic, saving, suspended, territorial, tertiary, tiered, tightening, transferring, transitioning, vest

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

SONN similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Sonnet BioTherapeutics Holdings, Inc. (the “Company”) on Form 10-Q for the quarter ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Pankaj Mohan, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1)	The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: February 13, 2025

/s/ Pankaj Mohan
Pankaj Mohan
President and Chief Executive Officer
(Principal Executive Officer)

The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.